4//SEC Filing
PRASAD SUYASH 4
Accession 0001209191-21-004572
CIK 0001806310other
Filed
Jan 19, 7:00 PM ET
Accepted
Jan 20, 8:21 PM ET
Size
5.5 KB
Accession
0001209191-21-004572
Insider Transaction Report
Form 4
PRASAD SUYASH
CMO and Head of R&D
Transactions
- Award
Stock Option (Right to Buy)
2021-01-19+80,000→ 80,000 totalExercise: $31.00Exp: 2031-01-19→ Common Stock (80,000 underlying)
Footnotes (1)
- [F1]25% of the total number of shares underlying the option shall vest and become exercisable on January 19, 2022 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Documents
Issuer
Taysha Gene Therapies, Inc.
CIK 0001806310
Entity typeother
Related Parties
1- filerCIK 0001679129
Filing Metadata
- Form type
- 4
- Filed
- Jan 19, 7:00 PM ET
- Accepted
- Jan 20, 8:21 PM ET
- Size
- 5.5 KB